| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.62 | 24.0% | 82.3% |
| Total Income | 0.62 | 24.0% | 82.3% |
| Expenditure | 4.41 | 7.6% | 111.0% |
| PBT | -3.73 | 6.0% | 86.5% |
| Net Profit | -3.73 | 6.0% | 86.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.91 | 1.1% | 405.6% |
SeaStar Medical Reports Q2 2026 Financial Results and Provides Business Updates
13 Aug 2026 · 13 Aug, 1:47 am
Summary
SeaStar Medical reported second quarter 2026 net revenue of approximately $0.6 million, an 82% increase compared to the second quarter of 2025, driven by expanded use of its QUELIMMUNE therapy in pediatric AKI. Gross margins remained strong at 91%. The company is advancing its NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients, with 223 of 339 patients enrolled. SeaStar Medical also secured dedicated ICD-10-PCS codes for its SCD therapy, which will facilitate hospital billing starting October 1, 2026. The net loss for the quarter was approximately $3.7 million, or $0.91 per share, an increase from the prior year's loss of $2.0 million, or $1.77 per share, primarily due to increased research and development and general and administrative expenses.
Key Highlights
- 1
SeaStar Medical added 3 top-rated children's hospitals to its QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue by 82% compared to the second quarter of 2025.
- 2
Net revenue for the second quarter of 2026 was approximately $0.6 million, an increase from approximately $0.3 million in the second quarter of 2025.
- 3
Gross margins for QUELIMMUNE remained strong at 91% for the three months ended June 30, 2026.
- 4
The company advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial, with 223 out of 339 adult AKI patients enrolled to date.
- 5
SeaStar Medical obtained dedicated ICD-10-PCS codes for its selective cytopheretic device (SCD) therapy, expected to take effect on October 1, 2026, enabling standardized inpatient hospital billing.
- 6
Net loss for the three months ended June 30, 2026, was approximately $3.7 million, or $0.91 per share, compared to a net loss of approximately $2.0 million, or $1.77 per share, for the same period in 2025.
Management Comments
Eric Schlorff
The enthusiasm for the use of our QUELIMMUNE therapy is resonating broadly throughout the pediatric critical care community. We believe our continued QUELIMMUNE revenue growth bodes well for our future potential opportunity in the adult AKI market that is 50 times larger than the current pediatric market in the U.S. We are keenly focused on achieving our enrollment target of 339 adult AKI patients in the NEUTRALIZE-AKI trial, and we are working with the FDA on our modular Premarket Approval (PMA) application for our SCD therapy as an organ-sparing and life-saving treatment for the adult patient population. With strong gross margins for QUELIMMUNE and universal ICD-10-PCS codes already established for our SCD therapies, we believe this first-in-class therapy for the treatment of adult patients with AKI has clear potential to both save lives and create significant shareholder value, should we obtain FDA approval.
Informational and educational content only. Not investment advice.